9.4 Lucentis

Quiz Module 9.4

Attention: you are not signed in!
To validate your answers and keep track of your progress please sign in or register a new account

1. Which of the anti-VEGF agents used for DME has been the most thoroughly studied?

a. Ranibizumab

b. Bevacizumab

c. Aflibercept

2. Which of the following is not correct?

a. For patients receiving combined ranibizumab and laser therapy, the best long-term visual outcomes were achieved with initiation of injections of ranibizumab followed by deferred laser therapy 6 months later.

b. Vision gains from ranibizumab injections in DME patients can be maintained with tapering of injection frequency over time.

c. Vision gains of ≥3 lines were experienced by a higher proportion of patients treated with laser than those treated with ranibizumab.

3. Which of the following studies demonstrated the efficacy and safety of ranibizumab for the treatment of DME?

a. BOLT

b. VIVID

c. VISTA

d. RESTORE

Summary

Read

Quiz Module 9.4

Beta version!

9.4 Lucentis

Summary

Read

Quiz Module 9.4